Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMWCLQ5)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
574013-66-4; CHEMBL192966; CHEBI:80003; FEX; (E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate; C32H36N2O3; AC1NS0YI; A1-01872; GTPL2744; Fexaramine, > SCHEMBL17083218; AOB5017; MolPort-023-276-486; EX-A2246; BCP15784; ZINC13831232; 3671AH; BDBM50167161; AKOS024457169; DB02545; CS-3884; NCGC00167776-01; HY-10912; AS-35318; AK175872; BC600742; KB-69557; RT-012704; B7108; C15649; BRD-K34170797-001-01-1
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
